Amgen (AMGN) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $5.67.
- Amgen's Debt to Equity fell 2927.73% to $5.67 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.67, marking a year-over-year decrease of 2927.73%. This contributed to the annual value of $10.23 for FY2024, which is 136.77% down from last year.
- According to the latest figures from Q3 2025, Amgen's Debt to Equity is $5.67, which was down 2927.73% from $7.57 recorded in Q2 2025.
- In the past 5 years, Amgen's Debt to Equity ranged from a high of $40.23 in Q1 2022 and a low of $3.5 during Q1 2021
- Over the past 5 years, Amgen's median Debt to Equity value was $9.24 (recorded in 2025), while the average stood at $10.34.
- In the last 5 years, Amgen's Debt to Equity surged by 104896.94% in 2022 and then tumbled by 7137.37% in 2023.
- Over the past 5 years, Amgen's Debt to Equity (Quarter) stood at $4.97 in 2021, then surged by 113.98% to $10.64 in 2022, then dropped by 2.54% to $10.37 in 2023, then fell by 1.37% to $10.23 in 2024, then plummeted by 44.51% to $5.67 in 2025.
- Its Debt to Equity stands at $5.67 for Q3 2025, versus $7.57 for Q2 2025 and $9.24 for Q1 2025.